Drug Trial Radar · NCT03592121
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
Last checked: Nov 19, 2026Latest source record: Mar 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3
Actual
Start
Jul 9, 2018
Primary completion
Oct 12, 2019
Study completion Oct 12, 2019
Sponsor
- Lead sponsor
- Applied Biology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2018
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
Conditions
- Sexual Dysfunction
- Sexual Arousal Disorder
- Sexual Dysfunction, Physiological
- Breast Cancer
- Nipple Disorder
- Neuropathy
- Cancer of Breast
Interventions
AB-101Drug
Apply approximately 1 hour prior to sexual activity
PlaceboDrug
Apply approximately 1 hour prior to sexual activity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Delayed Orgasm GradeTime frame: [baseline, week 8]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Southern CA Center for Sexual Health and Survivorship Medicine
Newport Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.